title: HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine.
abstract: The efficacy of the quadrivalent Human Papillomavirus (HPV) vaccine is thought to be mediated by humoral immunity. We evaluated the correlation between quadrivalent HPV vaccine-induced serum anti-HPV responses and efficacy. 17,622 women were vaccinated at day 1, and months 2 and 6. At day 1 and at 6-12 months intervals for up to 48 months, subjects underwent Papanicolaou and genital HPV testing. No immune correlate of protection could be found due to low number of cases. Although 40% of vaccine subjects were anti-HPV 18 seronegative at end-of-study, efficacy against HPV 18-related disease remained high (98.4%; 95% CI: 90.5-100.0) despite high attack rates in the placebo group. These results suggest vaccine-induced protection via immune memory, or lower than detectable HPV 18 antibody titers.
authors.affiliation: Department of Gynecology and Obstetrics, Medical University of Vienna, Vienna, Austria. elmar.joura@meduniwien.ac.at
authors.forename: Elmar A
authors.initials: EA
authors.lastname: Joura
authors.forename: Susanne K
authors.initials: SK
authors.lastname: Kjaer
authors.forename: Cosette M
authors.initials: CM
authors.lastname: Wheeler
authors.forename: Kristján
authors.initials: K
authors.lastname: Sigurdsson
authors.forename: Ole-Erik
authors.initials: OE
authors.lastname: Iversen
authors.forename: Mauricio
authors.initials: M
authors.lastname: Hernandez-Avila
authors.forename: Gonzalo
authors.initials: G
authors.lastname: Perez
authors.forename: Darron R
authors.initials: DR
authors.lastname: Brown
authors.forename: Laura A
authors.initials: LA
authors.lastname: Koutsky
authors.forename: Eng Hseon
authors.initials: EH
authors.lastname: Tay
authors.forename: Patricia
authors.initials: P
authors.lastname: García
authors.forename: Kevin A
authors.initials: KA
authors.lastname: Ault
authors.forename: Suzanne M
authors.initials: SM
authors.lastname: Garland
authors.forename: Sepp
authors.initials: S
authors.lastname: Leodolter
authors.forename: Sven-Eric
authors.initials: SE
authors.lastname: Olsson
authors.forename: Grace W K
authors.initials: GW
authors.lastname: Tang
authors.forename: Daron G
authors.initials: DG
authors.lastname: Ferris
authors.forename: Jorma
authors.initials: J
authors.lastname: Paavonen
authors.forename: Matti
authors.initials: M
authors.lastname: Lehtinen
authors.forename: Marc
authors.initials: M
authors.lastname: Steben
authors.forename: Xavier
authors.initials: X
authors.lastname: Bosch
authors.forename: Joakim
authors.initials: J
authors.lastname: Dillner
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Kurman
authors.forename: Slawomir
authors.initials: S
authors.lastname: Majewski
authors.forename: Nubia
authors.initials: N
authors.lastname: Muñoz
authors.forename: Evan R
authors.initials: ER
authors.lastname: Myers
authors.forename: Luisa L
authors.initials: LL
authors.lastname: Villa
authors.forename: Frank J
authors.initials: FJ
authors.lastname: Taddeo
authors.forename: Christine
authors.initials: C
authors.lastname: Roberts
authors.forename: Amha
authors.initials: A
authors.lastname: Tadesse
authors.forename: Janine
authors.initials: J
authors.lastname: Bryan
authors.forename: Lisa C
authors.initials: LC
authors.lastname: Lupinacci
authors.forename: Katherine E D
authors.initials: KE
authors.lastname: Giacoletti
authors.forename: Shuang
authors.initials: S
authors.lastname: Lu
authors.forename: Scott
authors.initials: S
authors.lastname: Vuocolo
authors.forename: Teresa M
authors.initials: TM
authors.lastname: Hesley
authors.forename: Richard M
authors.initials: RM
authors.lastname: Haupt
authors.forename: Eliav
authors.initials: E
authors.lastname: Barr
mesh_terms: D000293:Adolescent; D000914:Antibodies, Viral / Q000032:analysis / Q000096:biosynthesis* / Q000276:immunology*; D003218:Condylomata Acuminata / Q000453:epidemiology / Q000276:immunology / Q000517:prevention & control; D005260:Female; D005500:Follow-Up Studies; D052140:Human papillomavirus 11 / Q000276:immunology; D052162:Human papillomavirus 16 / Q000276:immunology; D052161:Human papillomavirus 18 / Q000276:immunology; D052163:Human papillomavirus 6 / Q000276:immunology; D006801:Humans; D007115:Immunization Schedule; D065006:Papanicolaou Test; D030361:Papillomavirus Infections / Q000276:immunology* / Q000473:pathology / Q000517:prevention & control*; D053918:Papillomavirus Vaccines / Q000276:immunology*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014621:Vagina / Q000473:pathology; D014626:Vaginal Smears; D014844:Vulva / Q000473:pathology; D055815:Young Adult
chemical_list: D000914:Antibodies, Viral; D053918:Papillomavirus Vaccines